Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Bone turnover biomarkers in COPD patients randomized to either a regular or shortened course of corticosteroids: a substudy of the randomized controlled CORTICO-COP trial

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Diurnal variation of magnesium and the mineral metabolism in patients with chronic kidney disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Heart failure associated with imported malaria: a nationwide Danish cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. High bone mineral density in lifelong trained female team handball players and young elite football players

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Long-term treatment with corticosteroids causes loss of bone density, but the effects of using short-term high-dose systemic-corticosteroid therapy to treat acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are unclear. Our aim was to determine whether high-dose corticosteroid therapy affected bone turnover markers (BTMs) to a greater extent compared to low-dose corticosteroid therapy.

METHODS: The CORTICO-COP trial (NCT02857842) showed that an eosinophil-guided corticosteroid intervention led to approximately 60% lower accumulated corticosteroid dose for hospitalized patients with AECOPD (low-dose group) compared with 5-day standard corticosteroid treatment (high-dose group). We compared the levels of BTMs C-terminal telopeptide of type 1 collagen (CTX) and procollagen type 1 N-terminal propeptide (P1NP) in 318 participants during AECOPD and at 1- and 3-month follow-up visits.

RESULTS: CTX decreased and P1NP increased significantly over time in both treatment groups. There were no significant differences between the groups at 1- or 3-months follow-up for P1NP. A significant drop in CTX was seen at 3 months (down Δ24% from the baseline, p = 0.017) for the high dose group.

CONCLUSION: Short-term, high-dose systemic corticosteroid treatment caused a rapid suppression of biomarkers of bone resorption. Corticosteroids did not suppress biomarkers of bone formation, regardless of patients receiving low or high doses of corticosteroids. This therapy was, therefore, harmless in terms of bone safety, in our prospective series of COPD patients.

TRIAL REGISTRATION: Identifier: NCT02857842 . Submitted August 2nd, 2016.

Original languageEnglish
Article number263
JournalRespiratory Research
Issue number1
Pages (from-to)263
Publication statusPublished - 12 Oct 2020

    Research areas

  • Adverse effects, Bone remodelling, Bone turnover markers, Chronic obstructive pulmonary disease, Corticosteroids

ID: 61030158